Schuster Alexander K, Wolfram Christian, Hudde Tobias, Klatt Alexander, Schnegelsberg Birthe, Midani-Oezkan Heven, Ross Mike, Ziemssen Focke, Pfeiffer Norbert
Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
J Clin Med. 2023 Jun 7;12(12):3881. doi: 10.3390/jcm12123881.
The use of OCT to monitor intravitreal treatment varies in clinical practice and is not always mandatory. The ALBATROS data collection aimed to clarify the impact of routinely implemented OCT on clinical outcomes and its impact on vision-related quality of life (VRQoL).
An observational cohort study included patients with retinal diseases starting an intravitreal anti-vascular endothelial growth factor treatment in Germany. Treatment followed clinical practice except mandatory OCT examination during the 12-month observation period. VRQoL was assessed by NEI VFQ-25 and compared with respect to OCT examinations and number of intravitreal injections in the different diseases (nAMD, DME, BRVO, CRVO).
1478 patients (74.5 ± 10.9 years, 54.9% female) were included in the analysis. Patients had neovascular AMD (65.2%), DME (18.4%), BRVO (9.5%), or CRVO (6.9%). 8.8 ± 2.6 OCT examinations and 6.1 ± 3.2 intravitreal injections were performed within 12 months. VRQoL differed between indications at baseline, with substantially lower values for neovascular AMD and CRVO. After twelve months, an increase in visual acuity and visual functional scale was observed for nAMD, DME, and BRVO, while in DME only, there was an association between number of OCT examinations and VRQoL.
Intravitreal treatment was able to maintain VRQoL over twelve months in a real-world setting. Regular OCT examinations were associated with higher gain in VRQoL in DME patients after 12 months.
在临床实践中，使用光学相干断层扫描（OCT）监测玻璃体内治疗的情况各不相同，并非总是必需的。ALBATROS数据收集旨在阐明常规实施的OCT对临床结局的影响及其对视力相关生活质量（VRQoL）的影响。
一项观察性队列研究纳入了在德国开始接受玻璃体内抗血管内皮生长因子治疗的视网膜疾病患者。治疗遵循临床实践，但在12个月的观察期内进行强制性OCT检查除外。通过NEI VFQ-25评估VRQoL，并就不同疾病（新生血管性年龄相关性黄斑变性[nAMD]、糖尿病性黄斑水肿[DME]、视网膜分支静脉阻塞[BRVO]、视网膜中央静脉阻塞[CRVO]）的OCT检查和玻璃体内注射次数进行比较。
1478例患者（74.5±10.9岁，54.9%为女性）纳入分析。患者患有新生血管性AMD（65.2%）、DME（18.4%）、BRVO（9.5%）或CRVO（6.9%）。在12个月内进行了8.8±2.6次OCT检查和6.1±3.2次玻璃体内注射。基线时，不同适应症的VRQoL有所不同，新生血管性AMD和CRVO的值显著较低。12个月后，观察到nAMD、DME和BRVO的视力和视觉功能量表有所增加，而仅在DME中，OCT检查次数与VRQoL之间存在关联。
在现实环境中，玻璃体内治疗能够在12个月内维持VRQoL。12个月后，定期OCT检查与DME患者VRQoL的更高改善相关。
